| Previous close | 158.70 |
| Open | 153.68 |
| Bid | 153.44 x 60000 |
| Ask | 154.92 x 60000 |
| Day's range | 153.68 - 153.68 |
| 52-week range | 119.00 - 168.80 |
| Volume | |
| Avg. volume | 246 |
| Market cap | 271.379B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 49.10 |
| EPS (TTM) | 3.13 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 5.77 (3.64%) |
| Ex-dividend date | 15 Jul 2024 |
| 1y target est | 127.01 |
Simply Wall St.With 72% ownership, AbbVie Inc. (NYSE:ABBV) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...
PR NewswireAbbVie to Host Second-Quarter 2024 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
ZacksAbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
© 2024 Yahoo. All rights reserved.